Pérez Ramírez, S.
del Monte-Millán, M.
López-Tarruella, S.
Martínez Jáñez, N.
Márquez-Rodas, I.
Lobo Samper, F.
Izarzugaza Perón, Y.
Rubio Terres, C.
Rubio Rodríguez, D.
García-Sáenz, J. Á.
Moreno Antón, F.
Zamora Auñón, P.
Arroyo Yustos, M.
Lara Álvarez, M. Á.
Ciruelos Gil, E. M.
Manso Sánchez, L.
Echarri González, M. J.
Guerra Martínez, J. A.
Jara Sánchez, C.
Bueno Muiño, C.
García Adrián, S.
Carrión Galindo, J. R.
Valentín Maganto, V.
Martín, M. http://orcid.org/0000-0001-9237-3231
Funding for this research was provided by:
Local health council at Madrid
Article History
Received: 25 March 2019
Accepted: 1 July 2019
First Online: 12 July 2019
Compliance with ethical standards
:
: SPR received consultant/advisory honorarium from Janssen, Novartis, Roche, Pharma-Mar and Bayer; SLTC received consultant/advisory honorarium from Astrazeneca, Novartis, Roche, Pfizer, Gelgene, Pierre-Fabre, Eissai and Lilly; NMJ received consultant/advisory honorarium from Roche, Amgen, Pfizer, Gelgene and Eissai; IMR received consultant/advisory honorarium from BMS, MSD, Novartis, Roche, Pierre-Fabre, Bioncotech and Sanofi; CRT received funding from Hospital General Universitario Gregorio Marañón; DRR received funding from Hospital General Universitario Gregorio Marañón; JAGS received consultant/advisory honorarium from Novartis, Lilly, Celgene and Roche and Funding from AstraZeneca; FMA received consultant/advisory honorarium from Roche, Pfizer, Novartis and AstraZeneca; PZA received consultant/advisory honorarium from Roche and Novartis; MLA received consultant/advisory honorarium from Novartis, Celgene, Roche and Pfizer; EMCG received remuneration from Novartis, Lilly, Pfizer, Roche and consultant/advisory honorarium from Sama; LMS received consultant/advisory honorarium from Tesaro, Astra-Zeneca, Roche, Novartis and Celgene, and funding from Tesaro; SGA reports personal fees from Celgene, Roche, Pierre Fabre, Novartis and Astra Zeneca and non-financial support from Roche, outside the submitted work; MM received remuneration from Pfizer, Lilly; consultant/advisory honorarium from Roche, Novartis, Pfizer, Astrazeneca, Lilly, Glaxo, PharmaMar, Taiho; and funding from Roche and Novartis. MDMM, FLS, YIP, MAY, MJEG, JAGM, CJS, CBM, RCG, VVM declare that they have no conflict of interest.
: This study has been approved by the Ethical Committee (Area 1 CEIm Hospital General Universitario Gregorio Marañón) and it has also been authorised by the local health council in Madrid and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
: All eligible patients provided written informed consent prior to the inclusion in the study.